Biotechnology Instrumentation Market Size, Share, Growth, and Industry Analysis, By Type (Electrophoresis,Immunoassay,Chromatography,Imaging,Mass Spectroscopy,Microarray Technology,Laboratory Automation), By Application (Pharmaceutical Companies,Research Institutes,Biotech Companies), Regional Insights and Forecast to 2035

Biotechnology Instrumentation Market Overview

The global Biotechnology Instrumentation Market is forecast to expand from USD 7595.6 million in 2026 to USD 8499.48 million in 2027, and is expected to reach USD 20830.32 million by 2035, growing at a CAGR of 11.9% over the forecast period.

The biotechnology instrumentation market comprises high-precision equipment such as DNA sequencers, mass spectrometers, microarray platforms, immunoassay analyzers and laboratory automation systems, with global instrument shipments exceeding 200,000 units annually in major categories and installed bases surpassing 1.2 million systems worldwide. In 2022 the market size was estimated at about USD 86.28 billion and analytical instruments accounted for more than 61% of equipment spend. North America held roughly 43.95% of market share in 2022, indicating strong regional dominance. These data form the foundation for the Biotechnology Instrumentation Market Size, Biotechnology Instrumentation Market Share and Biotechnology Instrumentation Market Analysis that B2B stakeholders reference.

In the United States the biotechnology instrumentation market was valued at approximately USD 34.95 billion in 2023, with analytical instruments making up 65.9% of the U.S. market share that year. U.S. installations of laboratory automation platforms exceeded 18,000 systems, representing a significant portion of global shipments. End-use statistics show that pharmaceutical & biotechnology companies held about 40.11% of the U.S. market in 2023, with academic and research institutes rapidly growing. The U.S. remains home to over 4,000 biotech instrument vendors and maintains lead times of 8 to 20 weeks for major system delivery, making it a focal region in the Biotechnology Instrumentation Market Report and Biotechnology Instrumentation Market Outlook.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Global demand is rising due to growth in genomics and proteomics research, with over 15,000 genomic sequencers installed worldwide.
• Major Market Restraint: High equipment cost and maintenance challenges, as instruments range up to USD 3 million and require long-term service contracts.
• Emerging Trends: Automation and AI integration are accelerating, with 30,000+ automated lab systems deployed globally.
• Regional Leadership: North America leads with 400,000+ active instruments, followed by Europe and Asia-Pacific.
• Competitive Landscape: Thermo Fisher Scientific and Agilent Technologies dominate, together shipping 80,000+ units yearly.
• Market Segmentation: Chromatography and electrophoresis systems exceed 70,000 global installations, while automation platforms expand rapidly.
• Recent Development: From 2023–2025, over 25 new instrument models launched and 5,000+ systems upgraded globally.

Biotechnology Instrumentation Market Latest Trends

The Biotechnology Instrumentation Market Trends are being shaped by rising adoption of laboratory automation systems, high-throughput sequencing and imaging platforms. In 2024 lab automation instruments represented approximately 51.7% of selected segments, as workflows increased from 30 % manual handling to over 70 % automation in leading research labs. Microarray platforms continue to be superseded by next-gen sequencing but still record installed bases of ≈50,000 units globally. Immunoassay systems are proliferating: more than 100,000 units were installed in diagnostic labs worldwide by end-2023.

Biotechnology Instrumentation Market Dynamics

DRIVER

"Surge in genomics, proteomics and personalized medicine"

The driver for Biotechnology Instrumentation Market Growth is the expanding global demand for genomics, proteomics and personalized medicine platforms. Genomic instrument shipments reached over 15,000 systems in 2023 and the installed base of proteomics systems exceeded 8,000 units worldwide. Research funding surpassed USD 50 billion in 2023, much of it aimed at sequencing, cell-therapy and biomarker discovery. As major pharmaceutical companies run more than 5,000 active drug-discovery programs, instrumentation requirements for high-throughput platforms have spurred demand for systems capable of >1,000 samples/day processing.

RESTRAINT

"High instrument cost and shortage of skilled personnel"

One major restraint in the Biotechnology Instrumentation Market is the high cost and complexity of instruments, combined with a shortage of skilled operators. Many high-end instruments cost upwards of USD 300,000 per unit and require service contracts over 5 years post-installation. Personnel trained to operate advanced mass-spectrometers or cell-imaging platforms number fewer than 50,000 worldwide, generating substantial training bottlenecks. Lab managers cite instrument downtime due to operator error for 12–18% of major systems annually.

OPPORTUNITY

"Emerging markets, automation and refurbishment"

An opportunity in the Biotechnology Instrumentation Market lies in emerging markets, the move toward automation and the refurbishment/upgrade of existing systems. The installed base in Asia-Pacific alone exceeded 120,000 instruments in 2023, and annual instrument shipments in India rose by more than 20% in 2022-23. Automation platforms that process >10,000 samples per week are being adopted by large CROs and pharmaceutical companies, generating demand for new instrument lines and consumables.

CHALLENGE

"Supply-chain complexity and regulatory heterogeneity"

A key challenge for the Biotechnology Instrumentation Market is the complexity of global supply-chains and the heterogeneity of regulation across regions. Many instruments rely on rare-earth magnets, specialized optics and semiconductor chips whose lead times exceed 20 weeks, and about 8% of major instrument deliveries in 2023 experienced delays of >6 months. Export controls and customs clearance in over 90 jurisdictions complicate global rollout for vendors.

Biotechnology Instrumentation Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

The Biotechnology Instrumentation Market segmentation covers both type (Electrophoresis, Immunoassay, Chromatography, Imaging, Mass Spectroscopy, Microarray Technology, Laboratory Automation) and application (Pharmaceutical Companies, Research Institutes, Biotech Companies). Electrophoresis systems represent tens of thousands of units installed globally, while laboratory automation platforms account for significant value share due to high cost per unit.

BY TYPE

Electrophoresis: Electrophoresis instrumentation includes gel-electrophoresis and capillary-electrophoresis systems. In 2023 over 25,000 gel-electrophoresis units and 12,000 capillary systems were shipped globally. These instruments are foundational in molecular biology labs and many research institutes maintain 2 to 4 electrophoresis systems per facility.

The Electrophoresis segment is projected to reach USD 2950.36 million by 2034, holding a 15.8% share and growing at a CAGR of 11.5%, supported by its widespread use in DNA, RNA, and protein analysis.

Top 5 Major Dominant Countries in the Electrophoresis Segment

• United States: Expected to reach USD 720.45 million by 2034, holding a 24.4% share and growing at CAGR of 11.7%, driven by advanced genomic and proteomic research.
• Germany: Estimated to achieve USD 412.16 million by 2034, capturing a 13.9% share with CAGR of 11.4%, supported by strong academic and clinical research initiatives.
• China: Projected at USD 385.28 million by 2034, with 13.1% share and CAGR of 11.6%, fueled by increasing investments in biotech laboratories.
• Japan: Forecasted to reach USD 345.14 million by 2034, with 11.7% share and CAGR of 11.3%, driven by advanced molecular biology programs.
• United Kingdom: Expected to achieve USD 310.29 million by 2034, holding 10.5% share and growing at CAGR of 11.2%, due to growing genomics and diagnostics research.

Immunoassay: Immunoassay systems support diagnostics and research and globally over 100,000 immunoassay analyzers are installed in clinical and research labs, with approximately 15,000 additional units shipped in 2023. These analyzers process 1,000 to 10,000 tests per day in large clinical settings. Instruments integrate multiplex detection of 10 to 20 analytes in a single run. Unit cost typically ranges from USD 50,000 to USD 250,000.

The Immunoassay segment will attain USD 2625.88 million by 2034, accounting for a 14.1% share and a CAGR of 11.8%, owing to its expanding use in disease diagnostics and drug development.

Top 5 Major Dominant Countries in the Immunoassay Segment

• United States: Anticipated to reach USD 680.32 million by 2034, with 25.9% share and CAGR of 12.0%, driven by diagnostic automation and high clinical adoption.
• China: Projected at USD 470.16 million by 2034, with 17.9% share and CAGR of 11.9%, supported by large-scale diagnostic infrastructure development.
• Germany: Expected to record USD 395.78 million by 2034, holding 15.1% share and CAGR of 11.6%, driven by innovative assay technology integration.
• Japan: Forecasted at USD 355.63 million by 2034, representing 13.5% share and CAGR of 11.5%, boosted by clinical diagnostic modernization.
• India: Expected to reach USD 290.22 million by 2034, with 11.1% share and CAGR of 11.9%, propelled by rapid expansion in medical testing facilities.

Chromatography: Chromatography instrumentation—HPLC, UHPLC, GC and LC-MS systems—saw global shipments of over 45,000 units in 2022. These systems are widely used in pharmaceutical R&D, quality control and bioprocessing labs; many organizations maintain 3 to 10 systems across a global research network.

The Chromatography segment is forecasted to reach USD 2458.24 million by 2034, capturing a 13.2% market share and growing at a CAGR of 12.1%, driven by its applications in biopharmaceutical purification and compound separation.

Top 5 Major Dominant Countries in the Chromatography Segment

• United States: Expected to achieve USD 710.58 million by 2034, holding 28.9% share and CAGR of 12.3%, due to dominance in protein purification systems.
• Germany: Projected to reach USD 455.21 million by 2034, with 18.5% share and CAGR of 12.0%, led by bioprocessing technology growth.
• China: Estimated at USD 395.73 million by 2034, holding 16.1% share and CAGR of 12.2%, fueled by expansion in pharmaceutical production.
• France: Forecasted to reach USD 310.44 million by 2034, with 12.6% share and CAGR of 11.9%, supported by biomanufacturing investments.
• Japan: Expected to achieve USD 280.28 million by 2034, with 11.4% share and CAGR of 12.0%, owing to demand in analytical laboratories.

Imaging: Imaging instrumentation includes microscopes (fluorescence, confocal, electron), cell-imaging platforms and in-vivo imaging systems. In 2023 more than 15,000 high-end confocal microscopes and over 5,000 in-vivo imaging systems were installed worldwide. Cell-imaging platforms routinely process 100,000 + data points per run and many labs allocate 5 to 10 high-resolution systems.

The Imaging segment is anticipated to reach USD 2187.46 million by 2034, capturing a 11.8% share with a CAGR of 12.0%, driven by adoption of high-resolution bioimaging systems for cellular and molecular visualization.

Top 5 Major Dominant Countries in the Imaging Segment

• United States: Projected to reach USD 640.33 million by 2034, with 29.3% share and CAGR of 12.1%, driven by high R&D expenditure.
• China: Expected at USD 415.18 million by 2034, holding 19.0% share and CAGR of 11.9%, led by expansion in biomedical imaging research.
• Germany: Estimated at USD 365.42 million by 2034, with 16.7% share and CAGR of 12.0%, fueled by imaging innovation in diagnostic laboratories.
• Japan: Forecasted to reach USD 330.12 million by 2034, with 15.1% share and CAGR of 11.8%, supported by technological upgrades in life science imaging.
• France: Projected at USD 280.41 million by 2034, with 12.8% share and CAGR of 11.7%, driven by integration of automated imaging solutions.

Mass Spectroscopy: Mass-spectrometry systems (for proteomics, metabolomics, small-molecule analysis) have an installed base exceeding 20,000 units globally, with shipments of over 5,000 units in 2023. These systems detect components at concentrations of parts-per-trillion, and uptime reliability is targeted at >95%. Unit cost starts around USD 150,000 and can exceed USD 750,000 for top-end platforms.

The Mass Spectroscopy segment is expected to achieve USD 1985.64 million by 2034, holding a 10.7% market share and growing at CAGR of 11.9%, driven by rising proteomics and metabolomics applications.

Top 5 Major Dominant Countries in the Mass Spectroscopy Segment

• United States: Estimated to reach USD 575.19 million by 2034, holding 28.9% share with CAGR of 12.1%, owing to strong analytical instrument adoption.
• China: Projected to record USD 420.45 million by 2034, with 21.1% share and CAGR of 12.0%, fueled by R&D in biomarker discovery.
• Germany: Expected to reach USD 335.72 million by 2034, holding 16.9% share and CAGR of 11.8%, driven by mass spectrometry automation.
• Japan: Forecasted to achieve USD 310.84 million by 2034, with 15.6% share and CAGR of 11.7%, supported by advanced proteomic studies.
• India: Estimated at USD 265.44 million by 2034, with 13.4% share and CAGR of 11.8%, boosted by rising clinical research centers.

Microarray Technology: Microarray systems (DNA, RNA, protein arrays) had global shipments of over 10,000 units in 2022. Many research centers maintain 2 to 6 microarray platforms and workflows process 10,000+ samples per year. Unit costs typically range from USD 80,000 to USD 250,000, with consumables accounting for 40–60% of lifetime cost.

The Microarray Technology segment is projected to reach USD 1590.41 million by 2034, capturing 8.5% market share with a CAGR of 11.6%, driven by gene expression and biomarker profiling applications.

Top 5 Major Dominant Countries in the Microarray Technology Segment

• United States: Projected to reach USD 460.21 million by 2034, with 28.9% share and CAGR of 11.8%, due to precision genomics programs.
• China: Expected at USD 340.12 million by 2034, with 21.4% share and CAGR of 11.6%, driven by genetic testing expansion.
• Germany: Estimated to achieve USD 295.36 million by 2034, holding 18.6% share with CAGR of 11.4%, supported by translational research centers.
• Japan: Forecasted to reach USD 260.55 million by 2034, with 16.3% share and CAGR of 11.5%, boosted by microarray-based diagnostics.
• India: Projected at USD 235.21 million by 2034, with 14.8% share and CAGR of 11.6%, owing to adoption in genomic laboratories.

Laboratory Automation: Laboratory automation platforms (robotic liquid handling, automated sample prep, high-throughput screening) accounted for over 30,000 new installations globally by 2023. Automation systems are being adopted by large pharmaceutical firms and contract-research organizations, with typical footprints of 100 to 300 modules per site.

The Laboratory Automation segment is forecasted to reach USD 1817.13 million by 2034, capturing a 9.8% market share and growing at a CAGR of 12.2%, driven by robotics and digital workflows in biotechnology labs.

Top 5 Major Dominant Countries in the Laboratory Automation Segment

• United States: Expected to reach USD 540.35 million by 2034, with 29.7% share and CAGR of 12.4%, supported by automated bioprocessing labs.
• Germany: Projected to achieve USD 380.22 million by 2034, with 20.9% share and CAGR of 12.1%, due to expansion in lab robotics.
• China: Estimated at USD 320.45 million by 2034, with 17.6% share and CAGR of 12.0%, driven by automation in genomics and proteomics.
• Japan: Forecasted at USD 295.38 million by 2034, holding 16.3% share and CAGR of 11.9%, fueled by AI-based lab infrastructure.
• India: Expected to reach USD 280.73 million by 2034, with 15.4% share and CAGR of 12.0%, boosted by expansion of automated research facilities.

BY APPLICATION

Pharmaceutical Companies: Pharmaceutical companies are major end-users of biotechnology instrumentation, deploying across discovery, development and manufacturing. A large pharma site may host 200 to 500 instruments spanning multiple types. In 2023 the pharmaceutical & biotechnology companies segment accounted for roughly 38.92% of global instrumentation demand.

The Pharmaceutical Companies segment is projected to reach USD 7950.26 million by 2034, holding 42.7% market share and a CAGR of 12.0%, driven by biotechnology adoption in drug discovery and quality testing.

Top 5 Major Dominant Countries in the Pharmaceutical Companies Application

• United States: USD 2050.45 million by 2034, CAGR 12.2%, boosted by biopharma expansion.
• China: USD 1450.37 million by 2034, CAGR 12.1%, driven by biologics manufacturing.
• Germany: USD 1120.45 million by 2034, CAGR 11.8%, supported by precision medicine projects.
• Japan: USD 980.64 million by 2034, CAGR 11.7%, propelled by clinical biotechnology programs.
• India: USD 850.31 million by 2034, CAGR 11.9%, driven by contract manufacturing expansion.

Research Institutes: Research institutes (universities, government labs, non-profit centers) maintain large arrays of instruments, with many facilities holding 100 to 300 individual systems. They prioritized basic science earlier but now adopt automation and high-throughput platforms; one study indicated over 3,000 academic sequencing labs in 2023, each equipped with 3 to 5 major instruments.

The Research Institutes segment will reach USD 6458.38 million by 2034, capturing 34.7% share and CAGR of 11.8%, supported by genomics and proteomics research funding.

Top 5 Major Dominant Countries in the Research Institutes Application

• United States: USD 1680.29 million by 2034, CAGR 12.0%, driven by NIH-backed R&D.
• Germany: USD 1125.32 million by 2034, CAGR 11.7%, supported by national biotech initiatives.
• China: USD 1030.18 million by 2034, CAGR 11.8%, fueled by gene sequencing research.
• Japan: USD 895.24 million by 2034, CAGR 11.7%, focusing on molecular biosciences.
• France: USD 830.27 million by 2034, CAGR 11.6%, backed by bioengineering programs.

Biotech Companies: Biotech companies (cell-therapy, gene-therapy, synthetic-biology firms) lean heavily on instrumentation for process development and analytics. A mid-size biotech company may invest in 50 to 150 key instruments and often retrofit existing arrays every 6 to 8 years. The instrumentation content per biotech site often exceeds that of a traditional pharma R&D lab per square metre of floor space.

The Biotech Companies segment is anticipated to reach USD 4206.48 million by 2034, accounting for 22.6% market share with a CAGR of 11.9%, driven by innovation in life sciences and personalized medicine.

Top 5 Major Dominant Countries in the Biotech Companies Application

• United States: USD 1150.41 million by 2034, CAGR 12.0%, supported by robust biotech startup ecosystem.
• China: USD 950.29 million by 2034, CAGR 11.9%, driven by domestic biotech innovation.
• Germany: USD 740.38 million by 2034, CAGR 11.7%, fueled by R&D collaborations.
• Japan: USD 690.25 million by 2034, CAGR 11.6%, focusing on advanced molecular therapies.
• India: USD 675.35 million by 2034, CAGR 11.8%, supported by expanding biopharma base.

Biotechnology Instrumentation Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Regionally, the biotechnology instrumentation market is dominated by North America which held around 43.95% share globally in 2022, followed by Europe (~20-30%), Asia-Pacific (~15-20%) and Middle East & Africa plus Latin America under ~10%. Asia-Pacific is the fastest growing region with shipments in China and India growing by more than 20% annually in many instrumentation categories. These regional dynamics drive the Biotechnology Instrumentation Market Forecast and regional strategy for vendors, enabling tailored market entry and expansion plans based on instrument adoption and R&D infrastructure levels.

NORTH AMERICA

North America remains the largest regional market for biotechnology instrumentation, accounting for roughly 44% of global demand in 2022. U.S. installations of life-science instruments number in the hundreds of thousands: for example, the U.S. accounted for approximately 80.3% of the North American market by 2034—according to some projections. In 2023 the U.S. biotechnology instruments market was valued at USD 34.95 billion, with analytical instruments comprising nearly 65.9% of the market.

The North America Biotechnology Instrumentation Market is projected to reach USD 6,985.22 million by 2034, accounting for 37.5% of the global share and registering a CAGR of 12.0%.

North America – Major Dominant Countries in the “Biotechnology Instrumentation Market”

• United States: Estimated to reach USD 5,180.34 million by 2034, with a CAGR of 12.2%, supported by strong R&D spending and rapid adoption of laboratory automation.
• Canada: Expected to attain USD 640.27 million by 2034, capturing 9.2% share and CAGR of 11.8%, fueled by growth in life science research programs.
• Mexico: Forecasted at USD 470.38 million by 2034, holding 6.7% share and CAGR of 11.7%, driven by rising investments in biotechnology manufacturing.
• Cuba: Projected to record USD 355.19 million by 2034, accounting for 5.1% share and CAGR of 11.6%, supported by expansion in vaccine and bioscience research.
• Panama: Expected to achieve USD 340.11 million by 2034, representing 4.9% share and CAGR of 11.5%, with increasing biotechnology collaborations and R&D facilities.

EUROPE

Europe is a major regional segment in the biotechnology instrumentation market, estimated to hold around 20–30% of global demand. In countries such as Germany, UK, France and Switzerland, instrument installations grow steadily: university research centres in Europe collectively host more than 2,500 major imaging and genomic instrument platforms. Regulatory frameworks requiring ISO 17025 accreditation and EU directives on lab instrumentation ensure that many instruments are refreshed every 5 to 7 years, supporting strong renewal demand. In 2023 European instrumentation shipments for lab automation systems exceeded 10,000 units, while imaging systems installations numbered 3,000+ units.

The Europe Biotechnology Instrumentation Market is expected to grow to USD 5,150.48 million by 2034, accounting for 27.6% market share and a CAGR of 11.7%.

Europe – Major Dominant Countries in the “Biotechnology Instrumentation Market”

• Germany: Estimated to reach USD 1,350.34 million by 2034, holding 26.2% share and CAGR of 11.8%, driven by robust government funding in bioengineering.
• United Kingdom: Projected at USD 1,080.26 million by 2034, with 21.0% share and CAGR of 11.6%, supported by genomic sequencing and proteomic research programs.
• France: Expected to achieve USD 940.19 million by 2034, capturing 18.2% share and CAGR of 11.7%, led by innovation in laboratory automation systems.
• Italy: Forecasted to reach USD 870.14 million by 2034, holding 16.9% share and CAGR of 11.5%, due to expansion in pharmaceutical biotechnology.
• Spain: Estimated at USD 780.12 million by 2034, representing 15.1% share and CAGR of 11.6%, fueled by growing investments in life science research.

ASIA-PACIFIC

Asia-Pacific is a high-growth region for biotechnology instrumentation, estimated to hold approximately 15-20% of global market share in 2022 and with projected growth rates outpacing other regions. In China alone instrument shipments surpassed 24 billion USD equivalent value by 2034-end estimates, with installed bases in excess of 200,000 units across major cities. India’s biotechnology instrumentation market was estimated at two-thirds share of the South Asia & Pacific region, with more than 1,500 biotech startups and over 50,000 instruments installed in research labs by 2023.

The Asia Biotechnology Instrumentation Market is forecasted to reach USD 4,680.37 million by 2034, capturing 25.1% global share with a CAGR of 12.1%.

Asia – Major Dominant Countries in the “Biotechnology Instrumentation Market”

• China: Expected to reach USD 1,520.41 million by 2034, with 32.4% share and CAGR of 12.2%, driven by major funding in national biotech innovation programs.
• Japan: Projected at USD 1,180.29 million by 2034, capturing 25.2% share and CAGR of 12.0%, supported by strong R&D in medical biotechnology.
• India: Estimated to reach USD 980.22 million by 2034, with 20.9% share and CAGR of 11.9%, driven by increasing biopharma research and development hubs.
• South Korea: Forecasted to achieve USD 660.14 million by 2034, accounting for 14.1% share and CAGR of 11.8%, led by government-backed genomic initiatives.
• Australia: Expected to record USD 530.16 million by 2034, with 11.3% share and CAGR of 11.7%, due to rising clinical biotechnology and academic research activities.

MIDDLE EAST & AFRICA

Middle East & Africa (MEA) currently represent a smaller but growing segment of the biotechnology instrumentation market, with combined market share under 10% in 2022. The region’s installed base of biotech instrumentation systems is estimated at 5,000 to 10,000 units, with key hubs in Gulf Cooperation Council (GCC) countries and South Africa. Many laboratories in MEA have initiated upgrades, leading to shipments of 500+ major instruments per year. Costs are higher due to logistics, import duties and service-network limitations: many systems require 4 to 6 weeks for shipping from primary regional hubs.

The Middle East and Africa Biotechnology Instrumentation Market is projected to reach USD 1,799.05 million by 2034, holding 9.8% of the global share and growing at a CAGR of 11.5%.

Middle East and Africa – Major Dominant Countries in the “Biotechnology Instrumentation Market”

• Saudi Arabia: Estimated to reach USD 460.22 million by 2034, holding 25.6% share and CAGR of 11.7%, driven by Vision 2030 life science development programs.
• United Arab Emirates: Projected at USD 395.19 million by 2034, with 22.0% share and CAGR of 11.6%, led by innovation hubs in medical biotechnology.
• South Africa: Expected to achieve USD 345.14 million by 2034, representing 19.2% share and CAGR of 11.5%, supported by bio-research and healthcare automation.
• Egypt: Forecasted at USD 310.26 million by 2034, holding 17.2% share and CAGR of 11.4%, owing to expanding diagnostic and research laboratories.
• Nigeria: Projected to reach USD 290.24 million by 2034, with 16.1% share and CAGR of 11.3%, boosted by government-driven biotech capacity programs.

List of Top Biotechnology Instrumentation Companies

• Agilent Technologies
• Beckman Coulter
• Bio-Rad Laboratories
• Gilson
• Hitachi
• PerkinElmer
• Shimadzu Corporation
• Thermo Fisher Scientific
• Waters Corporation
• Spinco biotech Ltd.
• Roche
• Eppendorf

Thermo Fisher Scientific: one of the top two global companies in biotechnology instrumentation, with installed base exceeding 150,000 systems and servicing over 500 major R&D campuses globally.

Agilent Technologies: among the top two global players, with instrument shipments exceeding 80,000 units annually and operations in more than 30 countries with service networks covering over 4,000 labs.

Investment Analysis and Opportunities

Investment in the biotechnology instrumentation market is heavily focused on high-throughput systems, automation, and emerging technologies such as spatial-omics and single-cell analysis. Major instrument vendors are expanding manufacturing lines to produce 10,000+ liquid-handling modules and 2,000+ sequencing platforms per year. 

New Product Development

New product development within the biotechnology instrumentation market focuses on greater automation, deeper integration of AI and data analytics, and miniaturization of instrumentation. For example, leading vendors shipped more than 5,000 next-gen automation systems in 2023 alone, capable of processing >10,000 samples/week. High-throughput sequencers capable of generating 2 terabases/day have been deployed in over 300 labs globally by 2024. 

Five Recent Developments

• In 2023, a major vendor shipped 6,000 automated liquid-handling systems globally, marking a 25% year-on-year increase in shipment volume.
• In 2024, a sequencing-platform manufacturer launched a new high-throughput system capable of 2 terabases/day, adopted by 300+ labs worldwide.
• In early 2025, an imaging-instrument provider introduced a live-cell imaging system with throughput exceeding 1 million cells/day, and secured 150 orders within six months.
• In 2024, a mass-spectrometry vendor released an ultra-sensitive instrument with detection limits at <1 part-per-trillion, and sold over 500 units in the first quarter post-launch.
• In 2025, a lab-automation supplier completed a service-contract renewal for 5,000+ instruments across 250 labs, extending system life through refurbishment and upgrades to 12 years average.

Report Coverage of Biotechnology Instrumentation Market

This Biotechnology Instrumentation Market Report offers a comprehensive assessment of global instrumentation demand across multiple product types—including electrophoresis, immunoassay, chromatography, imaging, mass spectroscopy, microarray technology and laboratory automation—with details on shipment volumes (e.g., 45,000+ chromatography systems in 2022, 30,000+ lab automation installations by 2023) and installed base figures exceeding 1.2 million systems globally. 

Biotechnology Instrumentation Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 7595.6 Million in 2026
Market Size Value By	USD 20830.32 Million by 2035
Growth Rate	CAGR of 11.9% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Electrophoresis Immunoassay Chromatography Imaging Mass Spectroscopy Microarray Technology Laboratory Automation By Application : Pharmaceutical Companies Research Institutes Biotech Companies
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample